Contract Research & Services
Contract Services

Contract Services News

View news from other Pharmaceutical sectors:
151-165 of 2371 results
Gilead Sciences launches new grants program to support HIV cure
Gilead Sciences announced that it will provide grants for up to three years to academic institutions, nonprofit organizations and community groups engaged in HIV cure activities.
Contract Research & Services > Contract Services > News
Eisai, PIQUR sign deal to investigate Halaven and PQR309 in patients with TNBC
Eisai and PIQUR Therapeutics have signed an agreement to conduct a Phase 1/2b clinical study to investigate PQR309 in combination with Halaven® (eribulin) in patients with triple-negative breast cancer (TNBC).
Contract Research & Services > Contract Services > News
Philogen expands research and development agreement with AbbVie
Philogen has entered into a second collaboration with AbbVie to discover and develop novel types of armed antibody products.
Contract Research & Services > Contract Services > News
NanoViricides inks deal with University of Pittsburgh for ocular resting of drug candidates
NanoViricides has entered into an agreement with the University of Pittsburgh for the testing of its nanoviricides drug candidates in standard animal models of ocular virus infections.
Contract Research & Services > Contract Services > News
Seattle Genetics unveils commercial and regulatory progress under ADCETRIS collaboration with Takeda
Seattle Genetics will receive a one-time $20m milestone payment under its ADCETRIS (brentuximab vedotin) collaboration with Takeda Pharmaceutical Company Limited (Takeda).
Contract Research & Services > Contract Services > News
Takeda secures rights to Mersana’s XMT-1522 outside US and Canada
Mersana Therapeutics and Takeda Pharmaceutical Company have entered a new strategic partnership granting Takeda rights to Mersana’s lead product candidate, XMT-1522, outside the US and Canada.
Contract Research & Services > Contract Services > News
Eisai, Esteve sign deal to co-promote anti-epilepsy drug Fycompa in Spain
Eisai has entered into a new agreement with Esteve to co-promote Fycompa (perampanel) in Spain from February 2016.
Contract Research & Services > Contract Services > News
Ligand inks OmniAb platform license deal with Tizona Therapeutics
Ligand Pharmaceuticals has entered into a worldwide license agreement with Tizona Therapeutics, an immunology company developing next generation therapies for cancer and autoimmune disease.
Contract Research & Services > Contract Services > News
Teva and AbCellera sign deal to discover rare monoclonal antibodies
Teva Pharmaceutical Industries and AbCellera have entered into a collaborative research agreement whereby AbCellera will apply its high-throughput single cell antibody platform for the discovery of rare monoclonal antibodies.
Contract Research & Services > Contract Services > News
Eisai acquires license from HUYA to develop HDAC inhibitor HBI-8000
Eisai has entered into an exclusive license agreement with HUYA Bioscience International to develop and market the oral histone deacetylase (HDAC) inhibitor HBI-8000 in Japan, South Korea, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Singapore.
Contract Research & Services > Contract Services > News
Bristol-Myers Squibb, Pfizer collaborate with Portola to develop andexanet alfa in Japan
Bristol-Myers Squibb and Pfizer have entered into a collaboration agreement with Portola Pharmaceuticals to develop and commercialize the investigational agent andexanet alfa in Japan.
Contract Research & Services > Contract Services > News
Avera Medical, Epic Sciences partner on cancer precision medicine clinical trials
Epic Sciences and Avera Medical Group have formed a collaboration on feasibility studies to better understand the effectiveness of personalized cancer treatments as part of novel ovarian and breast cancer clinical trials.
Contract Research & Services > Contract Services > News
Radius Health partners with Novartis to evaluate RAD1901 combination regimens in advanced breast cancer
Radius Health has entered into a worldwide clinical collaboration with Novartis Pharmaceuticals to evaluate the safety and efficacy of combining investigational agent RAD1901, a novel oral selective estrogen receptor degrader (SERD), with investigational agent LEE011 (ribociclib), a cyclin-dependent kinase (CDK) 4/6 inhibitor.
Contract Research & Services > Contract Services > News
Myeloma UK partners with SGC to accelerate discovery of myeloma treatment targets
Myeloma UK has entered into a new first-of-its-kind partnership to help bring treatments to myeloma patients faster.
Contract Research & Services > Contract Services > News
Pharnext partners with OrphanDev for phase 3 trial of PXT-3003 to treat CMT 1A
Pharnext has formed a collaboration with OrphanDev, a dedicated platform offering support in regulatory, methodology and logistics for rare diseases.
Contract Research & Services > Contract Services > News
151-165 of 2371 results